The use of anticonvulsants in the treatment of bipolar disorder

Handbook of Bipolar Disorder: Diagnosis and Therapeutic Approaches

Volumn , Issue , 2005, Pages 285-314

  Brambilla, Paolo ^a   Soares, Jair C ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053306097     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (218)

1. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 14:349-352.
2. Himmelhoch JM, Mulla D, Neil JF, Detre TP, Kupfer DJ. Incidence and significance of mixed affective states in a bipolar population. Arch Gen Psychiatry 1976; 33:1062-1066.
3. Maj M. The effect of lithium in bipolar disorder: a review of recent research evidence. Bipolar Disord 2003; 5:180-188.
4. Soares JC, Gershon S. The lithium ion: a foundation for psychopharmacological specificity. Neuropsychopharmacology 1998; 19:167-182.
5. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord 1986; 10:115-125.
6. Gaviria M, Flaherty J, Val E. A comparison of bipolar patients with and without a borderline personality disorder. Psychiatr J Univ Ott 1982; 7:190-195.
7. Prien RF, Potter WZ. NIMH workshop report on treatment of bipolar disorder. Psychopharmacol Bull 1990; 26:409-427.
8. Brambilla P, Barale F, Soares JC. Perspectives on the use of anticonvulsants in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2001; 4:421-446.
9. Brambilla P, Soares JC. The pharmacological treatment of acute mania. In: Dunner DL, Rosenbaum J, eds. Psychiatric Clinics of North America: Annual of Drug Therapy. Vol. Philadelphia, PA: W.B. Saunders Company, 2001:155-180.
10. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology (Berl) 2003; 166:315-332.
11. Birkhimer LJ, Curtis JL, Jann MW. Use of carbamazepine in psychiatric disorders. Clin Pharm 1985; 4:425-434.
12. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47:1969-1979.
13. Post RM, Uhde TW, Putnam FW, Ballenger JC, Berrettini WH. Kindling and carbama-zepine in affective illness. J Nerv Ment Dis 1982; 170:717-731.
14. Post RM, Rubinow DR, Uhde TW. Biochemical mechanisms of action of carbamaze-pine in affective illness and epilepsy. Psychopharmacol Bull 1984; 20:585-589.
15. Purdy RE, Julien RM, Fairhurst AS, Terry MD. Effect of carbamazepine on the in vitro uptake and release of norepinephrine in adrenergic nerves of rabbit aorta and in whole brain synaptosomes. Epilepsia 1977; 18:251-257.
16. Avissar S, Schreiber G, Aulakh CS, Wozniak KM, Murphy DL. Carbamazepine and electroconvulsive shock attenuate beta-adrenoceptor and muscarinic cholinoceptor coupling to G proteins in rat cortex. Eur J Pharmacol 1990; 189:99-103.
17. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000; 48:740-754.
18. Elphick M. An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics. Br J Psychiatry 1985; 147:198-200.
19. Folks DG, King LD, Dowdy SB, Petrie WM, Jack RA, Koomen JC, Swenson BR, Edwards P. Carbamazepine treatment of selected affectively disordered inpatients. Am J Psychiatry 1982; 139:115-117.
20. Kramlinger KG, Post RM. Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand 1989; 79:378-385.
21. Muller AA, Stoll K. Carbamazepine and oxcarbamazepine in the treatment of manic syndromes-studies in Germany. In: Emrich HM, Okuma T, Muller AA, eds. Anticon-vulsants in Affective Disorders. Amsterdam: Excerpta Medica, 1984:139-147.
22. Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr Neurol Jpn 1973; 27:283-297.
23. Okuma T, Yamashita I, Takahashi R, Itoh H, Kurihara M, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K. Clinical efficacy of carbamazepine in affective, schi-zoaffective, and schizophrenic disorders. Pharmacopsychiatry 1989; 22:47-53.
24. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic response to carbamazepine. Psychiatry Res 1987; 21:71-83.
25. Elphick M, Lyons F, Cowen PJ. Low tolerability of carbamazepine in psychiatric patients may restrict its clinical usefulness. J Psychopharmacol 1988; 2:1-4.
26. Jann MW, Saklad SR, Ereshefsky L. Carbamazepine for patients with affective target symptoms [letter]. Drug Intell Clin Pharm 1984; 18:81.
27. Centorrino F, Albert MJ, Berry JM, Kelleher JP, Fellman V, Line G, Koukopoulos AE, Kidwell JE, Fogarty KV, Baldessarini RJ. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord 2003; 5:370-374.
28. Ghaemi SN, Berv DA, Klugman J, Rosenquist KJ, Hsu DJ. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry 2003; 64:943-945.
29. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137:782-790.
30. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8:243-250.
31. Goncalves N, Stoll KD. Carbamazepine in manic syndromes. A controlled double-blind study. Nervenarzt 1985; 56:43-47.
32. Grossi E, Sacchetti E, Vita A, Conte G, Faravelli C, Hautman G, Zerbi D, Mesina AM, Drago F, Motta A. Carbamazepine vs chloropromazine in mania: a double blind trial. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam: Excerpta Medica, 1984:177-187.
33. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984; 41: 165-170.
34. Lenzi A, Lazzerini F, Grossi E, Massimetti G, Placidi GF. Use of carbamazepine in acute psychosis: a controlled study. J Int Med Res 1986; 14:78-84.
35. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987; 48:89-93.
36. Moller HJ, Kissling W, Riehl T, Bauml J, Binz U, Wendt G. Double blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13:127-136.
37. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe M. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology 1979; 66:211-217.
38. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990; 23:143-150.
39. Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, Small IF. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48:915-921.
40. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychophar-macol Bull 1995; 31:265-272.
41. Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65:478-484.
42. Sethi BB, Tiwari SC. Carbamazepine in affective disorders. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam: Excerpta Medica, 1984:167-176.
43. Stoll KD, Bisson HE, Fischer E, et al. Carbamazepine versus haloperidol in manic syndromes-first report of a multicentric study in Germany. In: Shagas C, Josiassen RC, Bridger WH, et al., eds. Biological Psychiatry 1985. Amsterdam: Elsevier, 1986:332-334.
44. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl) 2000; 150:15-23.
45. Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, Emslie GJ, Weinberg WA, Rush AJ. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000; 39:713-720.
46. Dilsaver SC, Swann SC, Chen YW, Shoaib A, Joe B, Krajewski KJ, Gruber N, Tsai Y. Treatment of bipolar depression with carbamazepine: results of an open study. Biol Psychiatry 1996; 40:935-937.
47. Ketter TA, Post RM, Parekh PI, Worthington K. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J Clin Psychiatry 1995; 56:471-475.
48. Kramlinger KG, Post RM. The addition of lithium to carbamazepine. Antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989; 46:794-800.
49. Post RM, Uhde TW, Ballenger JC, Chatterji DC, Greene RF, Bunney WE Jr. Carba-mazepine and its 10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. Arch Gen Psychiatry 1983; 40:673-676.
50. Prasad AJ. Efficacy of carbamazepine as an antidepressant in chronic resistant depressives. J Indian Med Assoc 1985; 83:235-237.
51. Roy-Byrne P, Uhde TW, Post RM, Joffe RT. Relationship of response to sleep deprivation and carbamazepine in depressed patients. Acta Psychiatr Scand 1984; 69:379-382.
52. Cullen M, Mitchell P, Brodaty H, Boyce P, Parker G, Hickie I, Wilhelm K. Carbama-zepine for treatment-resistant melancholia. J Clin Psychiatry 1991; 52:472-476.
53. Nassir Ghaemi S, Ko JY, Katzow JJ. Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review. Bipolar Disord 2002; 4:70-74.
54. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamaze-pine. Am J Psychiatry 1986; 143:29-34.
55. Neumann J, Seidel K, Wunderlich H-P. Comparative studies of the effect of carbama-zepine and trimipramine in depression. In: Emrich HM, Okumna T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam: Excerpta Medica, 1984:160-166.
56. Rybakowski JK, Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 1999; 40:134-139.
57. Kishimoto A, Ogura C, Hazama H, Inoue K. Long-term prophylactic effects of carba-mazepine in affective disorder. Br J Psychiatry 1983; 143:327-331.
58. Nolen WA. Carbamazepine, a possible adjunct or alternative to lithium in bipolar disorder. Acta Psychiatr Scand 1983; 67:218-225.
59. Post RM, Uhde TW, Ballenger JC, Squillace KM. Prophylactic efficacy of carbamaze-pine in manic-depressive illness. Am J Psychiatry 1983; 140:1602-1604.
60. Post RM, Leverich GS, Rosoff AS, Altshuler LL. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990; 10:318-327.
61. Shukla S, Cook BL, Miller MG. Lithium-carbamazepine versus lithium-neuroleptic prophylaxis in bipolar illness. J Affect Disord 1985; 9:219-222.
62. Stuppaeck C, Barnas C, Miller C, Schwitzer J, Fleischhacker WW. Carbamazepine in the prophylaxis of mood disorders. J Clin Psychopharmacol 1990; 10:39-42.
63. Svestka J, Nahunek K, Ceskova E, Korbicka J. Carbamazepine prophylaxis of affective psychoses (intraindividual comparison with lithium carbonate). Activ Nerv Suppl (Praha) 1985; 27:261-262.
64. Di Costanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatr Scand 1991; 83:456-459.
65. Fawcett J, Kravitz HM. The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants. J Clin Psychiatry 1985; 46:58-60.
66. Kishimoto A. The treatment of affective disorder with carbamazepine: prophylactic synergism of lithium and carbamazepine combination. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:483-493.
67. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsycho-biology 1993; 27:138-145.
68. Bellaire W, Demisch K, Stoll K-D. Carbamazepine vs lithium. Einsatz in der prophy-laxe rezidivierender affektiver und schizoaffectiver psychosen. Munch Med Wochenschr 1990; 132:82-86.
69. Cabrera JF, Muhlbauer HD, Schley J, Stoll KD, Muller-Oerlinghausen B. Long-term randomized clinical trial on oxcarbamazepine vs lithium in bipolar and schizoaffective disorders: preliminary reports. Pharmacopsychiatry 1986; 19:282-283.
70. Simhandl C, Denk E, Thau K. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord 1993; 28:221-231.
71. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology 1981; 73:95-96.
72. Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986; 47:490-494.
73. Watkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987; 150:180-182.
74. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153:198-204.
75. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85:114-118.
76. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58:470-478.
77. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA. Prophylactic effi-cacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64:144-151.
78. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychophar-macol 1998; 18:455-460.
79. Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharma-col 1999; 14:283-285.
80. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbama-zepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14:277-281.
81. Kleindienst N, Greil W. Inter-episodic morbidity and drop-out under carbamazepine and lithium in the maintenance treatment of bipolar disorder. Psychol Med 2002; 32:493-501.
82. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet 1988; 15:367-389.
83. Soares JC. Valproate treatment and the risk of hyperandrogenism and polycystic ovaries. Bipolar Disord 2000; 2:37-41.
84. Ueda Y, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp Brain Res 2000; 133:334-339.
85. Brambilla P, Perez J, Barale F, Schettini G, Soares JC. GABAergic dysfunction in mood disorders. Mol Psychiatry 2003; 8:721-737, 715.
86. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989; 50(suppl):23-29.
87. Shiah IS, Yatham LN, Lam RW, Zis AP. Effects of divalproex sodium on 5-HT1A receptor function in healthy human males: hypothermic, hormonal, and behavioral responses to ipsapirone. Neuropsychopharmacology 1997; 17:382-390.
88. Hahn CG, Friedman E. Abnormalities in protein kinase C signaling and the pathophy-siology of bipolar disorder. Bipolar Disord 1999; 2:81-86.
89. Chang MC, Contreras MA, Rosenberger TA, Rintala JJ, Bell JM, Rapoport SI. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 2001; 77: 796-803.
90. Chen B, Wang JF, Young LT. Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol Psychiatry 2000; 48:658-664.
91. Bown CD, Wang JF, Young LT. Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacol-ogy 2000; 39:2162-2169.
92. Sassi RB, Soares JC. Emerging therapeutic targets in bipolar mood disorder. Expert Opin Ther Targets 2001; 5:587-599.
93. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995; 56:118-121.
94. Brown R. U.S. experience with valproate in manic depressive illness: a multicenter trial. J Clin Psychiatry 1989; 50(suppl):13-16.
95. Guscott R. Clinical experience with valproic acid in 22 patients with refractory bipolar mood disorder [letter]. Can J Psychiatry 1992; 37:590.
96. McFarland BH, Miller MR, Straumfjord AA. Valproate use in the older manic patient. J Clin Psychiatry 1990; 51:479-481.
97. Papatheodorou G, Kutcher SP, Katic M, Szalai JP. The efficacy and safety of dival-proex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial. J Clin Psychopharmacol 1995; 15:110-116.
98. Prasad AJ. The role of sodium valproate as an anti-manic agent. Pharmatherapeutica 1984; 4:6-8.
99. Sharma V, Persad E, Mazmanian D, Karunaratne K. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993; 38:137-139.
100. Fogelson DL, Jacobson S, Sternbach H. A retrospective study of valproate in private psychiatric practice. Ann Clin Psychiatry 1991; 3:315-320.
101. McElroy SL, Keck PE Jr, Pope HG Jr. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7:16-24.
102. Stoll AL, Banov M, Kolbrener M, Mayer PV, Tohen M, Strakowski SM, Castillo J, Suppes T, Cohen BM. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14:311-313.
103. Tohen M, Castillo J, Pope HG Jr, Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14:67-70.
104. Papatheodorou G, Kutcher SP. Divalproex sodium treatment in late adolescent and young adult acute mania. Psychopharmacol Bull 1993; 29:213-219.
105. Brennan MJW, Sandyk E, Borsook D. Use of sodium valproate in the management of affective disorders: basic and clinical aspects. In: Emrich HM, Okumna T, Muller AA, eds. Anticonvulsants in Affective Disorders. Vol. 56-65. Amsterdam: Excerpta Medica, 1984.
106. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991; 48:62-68.
107. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149:108-111.
108. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271:918-924.
109. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A rando-mized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996; 57:142-146.
110. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000; 20:195-203.
111. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63:1148-1155.
112. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157:124-126.
113. Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993; 54:305-308.
114. Grunze H, Erfurth A, Amann B, Giupponi G, Kammerer C, Walden J. Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychophar-macol 1999; 19:303-309.
115. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63:442-446.
116. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67: 207-212.
117. Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 1996; 32:647-652.
118. Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993; 13:280-283.
119. Denicoff KD, Smith-Jackson EE, Bryan AL, Ali SO, Post RM. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154:1456-1458.
120. Jacobsen FM. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry 1993; 54:229-234.
121. Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. J Affect Disord 1984; 6:115-121.
122. Semademi GW. Etude clinique de l'effect normothymique du dipropylacetamide. Acta Psychiatrica Belgica 1976; 76:458-466.
123. Hayes SG. Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 1989; 50(suppl):35-39.
124. Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okumna T, Muller AA, eds. Anti-convulsants in Affective Disorders. Amsterdam: Excerpta Medica, 1984.
125. Niedermier JA, Nasrallah HA. Clinical correlates of response to valproate in geriatric inpatients. Ann Clin Psychiatry 1998; 10:165-168.
126. Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 1993; 54:380-384.
127. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ. A rando-mized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57:481-489.
128. Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A, Keller MB. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58:95-99.
129. Ghaemi SN, Goodwin FK. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. J Affect Disord 2001; 65:281-287.
130. Emilien G, Maloteaux JM, Seghers A, Charles G. Lithium therapy in the treatment of manic-depressive illness. Present status and future perspectives. A critical review. Arch Int Pharmacodyn Ther 1995; 330:251-278.
131. Czuczwar SJ. GABA-ergic system and antiepileptic drugs. Neurol Neurochir Pol 2000; 33:13-20.
132. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994; 44:S10-S16; discussion S31-S32.
133. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000; 280:107-110.
134. Fink K, Meder W, Dooley DJ, Gothert M. Inhibition of neuronal Ca(2) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000; 130:900-906.
135. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271:5768-5776.
136. Altshuler LL, Keck PEJ, McElroy SL, Suppes T, Brown ES, Denicoff K, Frye M, Gitlin M, Hwang S, Goodman R, Leverich G, Nolen W, Kupka R, Post R. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1999; 1:61-65.
137. Cabras PL, Hardoy MJ, Hardoy MC, Carta MG. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. J Clin Psychiatry 1999; 60:245-248.
138. Erfurth A, Kammerer C, Grunze H, Normann C, Walden J. An open label study of gabapentin in the treatment of acute mania. J Psychiatr Res 1998; 32:261-264.
139. Hardoy MJ, Hardoy MC, Carta MG, et al. Gabapentin in the treatment of bipolar disorders. Bipolar Disord 1999; 1:34.
140. Knoll J, Stegman K, Suppes T. Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. J Affect Disord 1998; 49:229-233.
141. McElroy SL, Soutullo CA, Keck PE Jr, Kmetz GF. A pilot trial of adjunctive gabapen-tin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997; 9:99-103.
142. Perugi G, Toni C, Ruffolo G, Sartini S, Simonini E, Akiskal H. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsy-chiatry 1999; 32:136-141.
143. Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder [letter]. Am J Psychiatry 1997; 154:291-292.
144. Sokolski KN, Green C, Maris DE, DeMet EM. Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann Clin Psychiatry 1999; 11:217-222.
145. Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 1998; 59:426-429.
146. Ryback RS, Brodsky L, Munasifi F. Gabapentin in bipolar disorder [letter]. J Neurop-sychiatry Clin Neurosci 1997; 9:301.
147. Vieta E, Martinez-Aran A, Nieto E, Colom F, Reinares M, Benabarre A, Gasto C. Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry 2000; 15:433-437.
148. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51: 253-260.
149. Pande AC, Crockatt JC, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2: 249-255.
150. Young LT, Robb JC, Hasey GM, MacQueen GM, Patelis Siotis I, Marriott M, Joffe RT. Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord 1999; 55: 73-77.
151. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42:535-541.
152. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40:985-991.
153. Afanas'ev I, Kudrin V, Rayevsky KS, Varga V, Saransaari P, Oja SS. Lamotrigine and carbamazepine affect differently the release of D-[3H]aspartate from mouse cerebral cortex slices: involvement of NO. Neurochem Res 1999; 24:1153-1159.
154. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27:490-497.
155. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38:119-130.
156. Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000; 39:2139-2146.
157. Vinod KY, Subhash MN. Lamotrigine induced selective changes in 5-HT(1A) receptor mediated response in rat brain. Neurochem Int 2002; 40:315-319.
158. Fogelson DL, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry 1997; 58:271-273.
159. Hoopes S. Lamotrigine in the treatment of bipolar depression and affective disorders: clinical experience in 218 patients [abstr]. Bipolar Disord 1999; 1:35.
160. Kusumakar V, Yatham LN. Lamotrigine treatment of rapid cycling bipolar disorder. Am J Psychiatry 1997; 154:1171-1172.
161. Lafer B, Tamada RS, Issler CK, Amaral JAMS, Moreno RA. Lamotrigine in treatment-refractory bipolar disorder. A Brazilian experience [abstr]. Bipolar Disord 1999; 1:39.
162. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17:185-189.
163. Bowden CL, Calabrese JR, McElroy SL, Rhodes LJ, Keck PE Jr, Cookson J, Anderson J, Bolden-Watson C, Ascher J, Monaghan E, Zhou J. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45:953-958.
164. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry 1996; 153:1236.
165. Calabrese JR, Bowden CL, McElroy SL, Cookson J, Andersen J, Keck PE Jr, Rhodes L, Bolden-Watson C, Zhou J, Ascher JA. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999; 156:1019-1023.
166. Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry 2003; 64:197-201.
167. Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsy-chopharmacol 1999; 9:119-123.
168. Anand A, Oren DA, Berman RM, et al. Lamotrigine treatment of lithium failure outpatient mania. A double blind placebo controlled trial. Bipolar Disord 1999; 1:23.
169. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60:79-88.
170. Laurenza A, Asnis G, Beaman M, Hudson J, Khan A, Londborg P, Monaghan E, Rudd D. A double blind, placebo controlled study supporting the efficacy of lamotri-gine (lamictal) in unipolar depression [abstr]. Bipolar Disord 1999; 1:39-40.
171. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group [in process citation]. J Clin Psychiatry 2000; 61:841-850.
172. Walden J, Schaerer L, Schloesser S, Grunze H. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar Disord 2000; 2:336-339.
173. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60:392-400.
174. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64:1013-1024.
175. Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72:145-148.
176. Bryant-Comstock L, Chang CN, Phillips S. Quality of life improvement in bipolar depressed patients treated with lamotrigine [abstr]. Bipolar Disord 1999; 1:25-26.
177. Fatemi SH, Rapport DJ, Calabrese JR, Thuras P. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997; 58:522-527.
178. Suppes T, Brown ES, McElroy SL, Keck PE Jr, Nolen W, Kupka R, Frye M, Denicoff KD, Altshuler L, Leverich GS, Post RM. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999; 53:95-98.
179. McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, Ascher J. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 2004; 65:204-210.
180. Doose DR, Walker SA, Gisclon LG, Nayak RK. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996; 36:884-891.
181. Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997; 19:1294-1308; discussion 1523-1524.
182. Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996; 24:73-77.
183. Kuzniecky R, Hetherington H, Ho S, Pan J, Martin R, Gilliam F, Hugg J, Faught E. Topiramate increases cerebral GABA in healthy humans. Neurology 1998; 51:627-629.
184. Gordey M, DeLorey TM, Olsen RW. Differential sensitivity of recombinant GABA(A) receptors expressed in Xenopus oocytes to modulation by topiramate. Epilepsia 2000; 41: S25-S19.
185. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41:S17-S20.
186. Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41:S10-S16.
187. Hanaya R, Sasa M, Ujihara H, Ishihara K, Serikawa T, Iida K, Akimitsu T, Arita K, Kurisu K. Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro. Brain Res 1998; 789:274-282.
188. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000; 41:S52-S60.
189. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhy-drase isoenzymes. Epilepsia 2000; 41:S35-S39.
190. Chengappa KNR, Rathore D, Levine J, Atzert R, Solai L, Parepally H, Levin H, Moffa N, Delaney J, Brar JS. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1:42-53.
191. Kusumakar V, Yatham LN, O'Donovan C, Kutcher SP. Topiramate augmentation in women with refractory rapid cycling bipolar disorder and significant weight gain from previous treatment. Bipolar Disord 1999; 1:38-39.
192. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47:1025-1033.
193. van Kammen DP, Calabrese JR, Shelton MD, et al. Topiramate in severe treatment refractory mania. Bipolar Disord 1999; 1:56.
194. Calabrese JR, Keck PE Jr, McElroy SL, Shelton MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21: 340-342.
195. Grunze HC, Normann C, Langosch J, Schaefer M, Amann B, Sterr A, Schloesser S, Kleindienst N, Walden J. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 2001; 62:464-468.
196. Bozikas VP, Petrikis P, Kourtis A, Youlis P, Karavatos A. Treatment of acute mania with topiramate in hospitalized patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:1203-1206.
197. Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:1035-1039.
198. Vieta E, Sanchez-Moreno J, Goikolea JM, Torrent C, Benabarre A, Colom F, Martinez-Aran A, Reinares M, Comes M, Corbella B. Adjunctive topiramate in bipolar II disorder. World J Biol Psychiatry 2003; 4:172-176.
199. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topir-amate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 4: 207-213.
200. Vieta E, Torrent C, Garcia-Ribas G, Gilabert A, Garcia-Pares G, Rodriguez A, Cadevall J, Garcia-Castrillon J, Lusilla P, Arrufat F. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol 2002; 22:431-435.
201. Vieta E, Goikolea JM, Olivares JM, Gonzalez-Pinto A, Rodriguez A, Colom F, Comes M, Torrent C, Sanchez-Moreno J. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry 2003; 64:834-839.
202. Vieta E, Sanchez-Moreno J, Goikolea JM, Colom F, Martinez-Aran A, Benabarre A, Corbella B, Torrent C, Comes M, Reinares M, Brugue E. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004; 24:374-378.
203. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50:245-251.
204. Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999; 156:968-969.
205. Kaufman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 1998; 10:181-184.
206. Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder [letter]. Am J Psychiatry 1999; 156:2014-2015.
207. Schaffer LC, Schaffer CB, Howe J. An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 2002; 71:259-263.
208. Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60: 759-762.
209. Suppes T, Chisholm KA, Dhavale D, Frye MA, Altshuler LL, McElroy SL, Keck PE, Nolen WA, Kupka R, Denicoff KD, Leverich GS, Rush AJ, Post RM. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 2002; 4:283-289.
210. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000; 157:463-465.
211. Hayes SG. Barbiturate anticonvulsants in refractory affective disorders. Ann Clin Psychiatry 1993; 5:35-44.
212. Schaffer LC, Schaffer CB, Caretto J. The use of primidone in the treatment of refractory bipolar disorder. Ann Clin Psychiatry 1999; 11:61-66.
213. Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, Kinoshita N, et al. The first open study of zonisamide, a novel anticonvul-sant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:707-715.
214. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11:722-733.
215. Gupta S, Masand PS, Frank B, Turner KL, Keller P. Topiramate in bipolar and schizoaffective disorder: mood stabilizing properties in treatment refractory patients [abstr]. Int J Neuropsychopharmacol 2000; 3(S1):334.
216. Carpenter LL, Leon Z, Yasmin S, Price LH. Do obese depressed patients respond to topiramate? A retrospective chart review. J Affect Disord 2002; 69:251-255.
217. Richens A, Davidson DL, Cartlidge NE, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiatry 1994; 57:682-687.
218. Levine J, Chengappa R, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000; 2:120-130.